Product Inquiry
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Bosakitug | BSI-045B; TQC-2731; TQC2731 | Phase 3 Clinical | Biosion Inc | Nasal Polyps; Sinusitis; Asthma; Pulmonary Disease, Chronic Obstructive; Dermatitis, Atopic | Details |
| Ecleralimab | CSJ-117; NOV-14 | Phase 2 Clinical | Novartis Pharma Ag | Asthma; Pulmonary Disease, Chronic Obstructive | Details |
| WIN-1001X | WIN-1001X | Phase 2 Clinical | Whanin Pharmaceutical Co Ltd | Nerve Degeneration; Parkinson Disease | Details |
| PF-07275315 | PF-07275315 | Phase 2 Clinical | Pfizer Inc | Dermatitis, Atopic | Details |
| Lunsekimig | SAR-443765 | Phase 2 Clinical | Sanofi | Nasal Polyps; Asthma; Sinusitis; Inflammation | Details |
| AZD-8630 | AZD-8630; AMG-104 | Phase 2 Clinical | Astrazeneca Plc, Amgen Inc | Asthma | Details |
| SHR-1905 | SHR-1905; AIO-001 | Phase 2 Clinical | Nasal Polyps; Respiratory Tract Diseases; Sinusitis; Asthma; Pulmonary Disease, Chronic Obstructive | Details | |
| CM-326(Connaught Biomedical Technology) | CM-326 | Phase 2 Clinical | Keymed Biosciences Co Ltd | Nose Diseases; Nasal Polyps; Asthma; Sinusitis; Pulmonary Disease, Chronic Obstructive; Dermatitis, Atopic | Details |
| PF-06342674 | RN-168; PF-6342674; PF-06342674; ZB-168 | Phase 1 Clinical | Pfizer Inc | Diabetes Mellitus, Type 1; Multiple Sclerosis | Details |
| HBM-9378 | SKB378; HBM-9378 | Phase 1 Clinical | Harbour Biomed, Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Asthma | Details |
| HB-0056 | HB-0056; HB0056 | Phase 1 Clinical | Shanghai Huaota Biopharmaceutical Co Ltd | Asthma | Details |
| IBI-3002 | IBI3002; IBI-3002 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Asthma | Details |
| GB-0895 | GB-0895 | Phase 1 Clinical | Immune System Diseases; Asthma | Details | |
| STSA-1201 | STSA-1201; STSA1201 | Phase 1 Clinical | Asthma | Details | |
| LQ043H | LQ043H | Phase 1 Clinical | Shanghai Novamab Biopharmaceuticals Co Ltd | Asthma | Details |
| GR2002 | GR2002 | Phase 1 Clinical | Genrix (Shanghai) Biopharmaceutical Co Ltd | Nasal Polyps; Asthma; Sinusitis; Dermatitis, Atopic | Details |
| QX-008N | QX008N; QX-008N | Phase 1 Clinical | Qyuns Therapeutics Co Ltd | Asthma; Pulmonary Disease, Chronic Obstructive | Details |
| BD-9 | BD-9 | Biolojic Design Inc | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Tezepelumab | AMG-157; MEDI-9929 | Approved | Amgen Inc | Tezspire | United States | Asthma | Astrazeneca Ab | 2021-12-17 | Eosinophilic Esophagitis; Hypersensitivity; Dermatitis, Atopic; Hypersensitivity, Immediate; Bronchial Diseases; Pulmonary Disease, Chronic Obstructive; Respiratory Hypersensitivity; Sinusitis; Asthma; Granulomatosis with Polyangiitis; Lung Diseases; Immune System Diseases; Chronic Urticaria; Respiratory Tract Diseases; Nasal Polyps; Anaphylaxis; Carcinoma; Lung Diseases, Obstructive | Details |